Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
Article Details
- CitationCopy to clipboard
Leo RJ, Brooks VL
Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
Curr Opin Investig Drugs. 2006 Jul;7(7):637-42.
- PubMed ID
- 16869117 [ View in PubMed]
- Abstract
Milnacipran is a serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor currently available for use as an antidepressant in several countries. Phase III clinical trials are currently underway to assess its potential role in the treatment of fibromyalgia syndrome, and in pursuit of US Food and Drug Administration approval for this indication. Evidence has accumulated suggesting that in animal models, milnacipran may exert pain-mitigating influences involving NE- and 5-HT-related processes at supraspinal, spinal and peripheral levels of pain transmission. Preliminary evidence suggests that milnacipran may be useful in mitigating pain and fatigue associated with fibromyalgia. However, its role in addressing comorbidities associated with fibromyalgia, including visceral pain and migraine, has yet to be investigated.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Milnacipran Sodium-dependent noradrenaline transporter Protein Humans YesInhibitorDetails Milnacipran Sodium-dependent serotonin transporter Protein Humans YesInhibitorDetails